Cigna (CI) Offering Possible 40.85% Return Over the Next 21 Calendar Days

Cigna's most recent trend suggests a bearish bias. One trading opportunity on Cigna is a Bear Call Spread using a strike $210.00 short call and a strike $215.00 long call offers a potential 40.85% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $210.00 by expiration. The full premium credit of $1.45 would be kept by the premium seller. The risk of $3.55 would be incurred if the stock rose above the $215.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Cigna is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Cigna is bearish.

The RSI indicator is at 43.73 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Cigna

Cigna (CI) Extends Medicare Advantage in North Carolina
Tue, 24 Nov 2020 23:01:11 +0000
Cigna (CI) is providing Medicare Advantage business in 63 new counties within the state of North Carolina.

Why Now May Be the Time to Buy Health Care Stocks
Tue, 24 Nov 2020 12:30:00 +0000
Stocks of health-care companies are cheap in historical terms, and the recent election results are a positive for those businesses.

Cigna Affordable Care Act Health Plans to Expand into 63 New Counties Across North Carolina for 2021
Mon, 23 Nov 2020 14:00:00 +0000
Cigna is expanding access to health coverage through the Affordable Care Act (ACA) marketplace in 63 counties across North Carolina for 2021. Cigna's plans on the individual exchange will include a number of features that increase access to quality health care – all while holding down out-of-pocket costs.

GoodRx downplays feared Amazon effect: Pharmacy ‘not particularly impactful to our business'
Fri, 20 Nov 2020 23:20:42 +0000
“I’m sure Amazon would love to ship your medications to you, but it’s really, really hard to do,” GoodRx's CEO explained to Yahoo Finance on Friday.

GoodRx CEO Shrugs Off $5 Billion Dive on Amazon Pharma Move
Fri, 20 Nov 2020 15:04:07 +0000
(Bloomberg) — Newly-listed GoodRx Holdings Inc. got caught in the crosshairs of Amazon.com Inc.’s latest plans to shake up the drug industry, triggering a wipeout of about $5 billion in market value in just two days. But its chief executive officer is shrugging it off.The Santa Monica, California-based company, mostly known for its prescription-drug pricing app, plunged to a record low of $33.51 on Wednesday in the wake of Amazon’s plans to sell medicines to its U.S. Prime members. GoodRx drew its first analyst downgrades after the news, with some saying Amazon’s foray could dampen the company’s growth.GoodRx Squarely in Amazon Crosshairs With Pharmacy Launch: ReactGoodRx shares have rebounded more than 15% in the last two trading sessions, though the stock has still shed more than 30% of its value from an Oct. 6 high. Wall Street analysts are split about its future returns, with seven buy-rated followers compared to six with hold equivalents and one sell. At least one analyst has upgraded the stock.Co-founder and chief executive officer Douglas Hirsch dismissed some of the gloom. The business of mail orders for medicines is challenging, he said, and even with the pandemic and regional lockdowns, the number of Americans getting their medicines through the mail has lingered at around just 5%.“Mail order is really hard. The road is littered with companies that tried to offer mail order,” Hirsch told Bloomberg News.A handful of analysts and industry experts were ambivalent about the move, suggesting Amazon was joining the drug distribution channel but won’t fundamentally change it.Amazon has so far only tapped Inside Rx, a unit of Cigna Corp.’s pharmacy benefit manager Express Scripts as a partner. Amazon’s discount card may also just be a way for it to adhere to regulations around publishing drug prices, according to analysts at RBC Capital Markets.Hirsch said GoodRx can survive the blow of increased competition because of the high barriers to entry for new players in the space. GoodRx’s relationships with most PBMs, as well Inside Rx, means it’s able to offer better pricing on medicines than most of Amazon’s cash discounts.“They are our partner, it’s not a winner take all scenario,” said Hirsch, who noted you can also use a GoodRx card on Amazon.Amazon representatives didn’t respond to emailed requests for comment.Buying OpportunityInvestor Eric Jackson, founder of EMJ Capital Ltd., agrees with Hirsch. He took a chance on this week’s rout and picked up shares of GoodRx for his hedge fund.“On day one, Amazon announces that the Death Star is coming in to kill the business and the stock collapses and people panic,” Jackson said. “Looking back, it turns out to be a great buying opportunity from those kind of blood-in-the-streets type moments and I think this will be the same for their GoodRx.”The tech-focused hedge fund manager pointed to similar competitive fears for Twilio Inc. and Roku Inc.Twilio has surged more than 1,000% since September 2017 when investors fled the stock on Amazon’s promise to offer similar texting features as the cloud computing company. Roku has advanced more than 260% after a double-threat from Apple and Amazon last year.“I’ve seen this movie before many times: Amazon is going to kill company X,” Jackson said. “It rarely works out.”(Updates share moves in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.